73 related articles for article (PubMed ID: 4208713)
21. In vitro-in vivo correlation of drug metabolism--deamination of 1- -D-arabinofuranosylcytosine.
Dedrick RL; Forrester DD; Ho DH
Biochem Pharmacol; 1972 Jan; 21(1):1-16. PubMed ID: 4500983
[No Abstract] [Full Text] [Related]
22. Plasma and cerebrospinal fluid pharmacokinetics of 1-beta-D-arabinofuranosylcytosine and 1-beta-D-arabinofuranosyluracil following the repeated intravenous administration of high- and intermediate-dose 1-beta-D-arabinofuranosylcytosine.
Damon LE; Plunkett W; Linker CA
Cancer Res; 1991 Aug; 51(16):4141-5. PubMed ID: 1868435
[TBL] [Abstract][Full Text] [Related]
23. Enhancement by tetrahydrouridine of 1-beta-D-arabinofuranosylcytosine (cytarabine) oral activity in L1210 leukemic mice.
Neil GL; Moxley TE; Manak RC
Cancer Res; 1970 Aug; 30(8):2166-72. PubMed ID: 4990003
[No Abstract] [Full Text] [Related]
24. Simultaneous determination of cytosine arabinoside and its metabolite, uracil arabinoside, in human plasma using hydrophilic interaction liquid chromatography with UV detection.
Uchiyama M; Takamatsu Y; Ogata K; Matsumoto T; Jimi S; Tamura K; Hara S
Biomed Chromatogr; 2013 Jul; 27(7):818-20. PubMed ID: 23420764
[TBL] [Abstract][Full Text] [Related]
25. Separation of 5'-mono-, di- and triphosphates of 1-beta-D-arabinofuranosylcytosine and of 1-beta-D-arabinofuranosyluracil by thin-layer and high pressure liquid chromatography.
Kreis W; Greenspan A; Woodcock T; Gordon C
J Chromatogr Sci; 1976 Jul; 14(7):331-3. PubMed ID: 956325
[TBL] [Abstract][Full Text] [Related]
26. Relationship of 1-beta-D-arabinofuranosylcytosine in plasma to 1-beta-D-arabinofuranosylcytosine 5'-triphosphate levels in leukemic cells during treatment with high-dose 1-beta-D-arabinofuranosylcytosine.
Liliemark JO; Plunkett W; Dixon DO
Cancer Res; 1985 Nov; 45(11 Pt 2):5952-7. PubMed ID: 4053067
[TBL] [Abstract][Full Text] [Related]
27. Effects of 1-beta-D-arabinofuranosylcytosine hydrochloride on regenerating bone marrow.
Papac RJ; Calabresi P; Hollingsworth JW; Welch AD
Cancer Res; 1965 Oct; 25(9):1459-62. PubMed ID: 5323960
[No Abstract] [Full Text] [Related]
28. Pharmacology and toxicology of a seven-day infusion of 1-beta-D-arabinofuranosylcytosine plus uridine in dogs.
Perlow L; Ohnuma T; Andrejczuk A; Shafir M; Strauchen J; Holland JF
Cancer Res; 1985 Jun; 45(6):2572-7. PubMed ID: 3986795
[TBL] [Abstract][Full Text] [Related]
29. In vivo studies on high-dose 1-beta-D-arabinofuranosylcytosine (HDara-C) and 1-beta-D-arabinofuranosyluracil (ara-U) with respect to pharmacokinetics, cell kinetics, and cytotoxicity in a rat myelocytic leukemia model (BNML).
Colly LP; Willemze R; Honders W; vd Hoorn F; Edelbroek PM
Semin Oncol; 1985 Jun; 12(2 Suppl 3):49-54. PubMed ID: 3859932
[TBL] [Abstract][Full Text] [Related]
30. Pharmacological disposition in mice of O 2 :2'-anhydro-1- -D-arabinosylcytosine 3'-phosphate, a potential antileukemic agent.
Focke JH; Broussard WJ; Nagyvary J
Biochem Pharmacol; 1973 Mar; 22(6):703-13. PubMed ID: 4693492
[No Abstract] [Full Text] [Related]
31. Preparation and antitumor activity of 4'-thio analogs of 2,2'-anhydro-1-beta-D-arabinofuranosylcytosine.
Ototani N; Whistler RL
J Med Chem; 1974 May; 17(5):535-7. PubMed ID: 4830257
[No Abstract] [Full Text] [Related]
32. Nucleosides. XCI. Some chemical properties of the antileukemic agent 2,2'-anhydro-1-beta-D-arabinofuranosyl-5-fluorocytosine.
Fox JJ; Otter BA
Ann N Y Acad Sci; 1975 Aug; 255():59-70. PubMed ID: 1059375
[No Abstract] [Full Text] [Related]
33. [Treatment of acute leukemia with 2,2'-anhydro-1-beta-D-arabinofuranosylcytosine hydrochloride (cyclocytidine) (author's transl)].
Masaoka T; Hasegawa Y; Tatsumi N; Nakamura H; Yoshitake J
Rinsho Ketsueki; 1973 Aug; 14(8):877-81. PubMed ID: 4797128
[No Abstract] [Full Text] [Related]
34. Continuous infusion of high-dose 1-beta-D-arabinofuranosylcytosine: a phase I and pharmacological study.
Spriggs DR; Robbins G; Takvorian T; Kufe DW
Cancer Res; 1985 Aug; 45(8):3932-6. PubMed ID: 4016760
[TBL] [Abstract][Full Text] [Related]
35. Correspondence Re: L.E. Damon et al., Plasma and cerebrospinal fluid pharmacokinetics of 1-beta-D-arabinofuranosylcytosine and 1-beta-D-arabinofuranosyluracil following the repeated intravenous administration of high- and intermediate-dose 1-beta-D-arabinofuranosylcytosine. Cancer Res., 51: 4141-4145, 1991.
Kreis W; Budman DR
Cancer Res; 1992 Jul; 52(13):3818-20. PubMed ID: 1617654
[No Abstract] [Full Text] [Related]
36. Studies on the Vilsmeier-Haack reaction. IV. Convenient synthesis of 2,2'-anhydro-1- -D-arabinofuranosylcytosine (2,2'-cyclocytidine) and its derivatives.
Kikugawa K; Ichino M
J Org Chem; 1972 Jan; 37(2):284-8. PubMed ID: 5013349
[No Abstract] [Full Text] [Related]
37. Sensitive radioimmunoassay for cytarabine and uracil arabinoside in plasma.
Sato T; Morozumi M; Kodama K; Kuninaka A; Yoshino H
Cancer Treat Rep; 1984 Nov; 68(11):1357-66. PubMed ID: 6498853
[TBL] [Abstract][Full Text] [Related]
38. Extraction and analytic procedures for cytosine arabinoside and 1-beta-D-arabinofuranosyluracil and their 5'-mono-, di-, and tri-phosphates.
Kreis W; Gordon C; Gizoni C; Woodcock T
Cancer Treat Rep; 1977 Jul; 61(4):643-6. PubMed ID: 195728
[TBL] [Abstract][Full Text] [Related]
39. Degradation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in human leukemic myeloblasts and lymphoblasts.
Jamieson GP; Finch LR; Snook M; Wiley JS
Cancer Res; 1987 Jun; 47(12):3130-5. PubMed ID: 3472653
[TBL] [Abstract][Full Text] [Related]
40. Rational design of arabinosyl nucleosides as antitumor and antiviral agents.
Müller WE
Jpn J Antibiot; 1977 Dec; 30 Suppl():104-20. PubMed ID: 612702
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
